Akorn, Inc. has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals for the development of an ANDA oral drug product for women’s healthcare. Financial terms of the agreement were not disclosed. Sofgen will be responsible for development and manufacturing of the drug and Akorn will be responsible for the regulatory submission, marketing and distribution in the U.S. and PR. The two companies are expected to begin a Bioequivalence study this Octobe...